

Press release

Lund 26 May 2021

Scandinavian ChemoTech AB has received approval for the CE marking

Scandinavian ChemoTech has been informed that we have now reached the final step of our CE certification approval for the IQwave™ and its platform, Tumour Specific Electroporation (TSE) and will receive its certificate shortly.

"It is an important milestone that now has been reached. This unique and patented technology will be able to give cancer patients and physicians a new effective weapon in the fight against resistant cancer tumours. I would like to take this opportunity to thank the organisation that has worked hard to achieve this status of our system and method." - says Mohan Frick, CEO Scandinavian ChemoTech AB

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00, E-mail: certifiedadviser@penser.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Wednesday 26th of May 2021 at 10.15 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se